目的 探讨复方血栓通胶囊联合盐酸阿罗洛尔片治疗不稳定型心绞痛的临床疗效。方法 选取2023年3月—2026年1月在徐州市中心医院就诊的120例不稳定型心绞痛患者，以随机数字表法将患者分为对照组和治疗组，各60例。对照组服用盐酸阿罗洛尔片，1片/次，2次/d。治疗组在对照组治疗基础上服用复方血栓通胶囊，3粒/次，3次/d。两组持续治疗3个月。比较两组患者的临床疗效、西雅图心绞痛量表（SAQ）评分、心绞痛症状指标、心功能指标、血清指标。结果 治疗组的总有效率为93.33%，对照组的总有效率为78.33%，组间差异显著（P＜0.05）。两组治疗后的SAQ评分均高于治疗前（P＜0.05），且治疗组治疗后的SAQ评分明显高于对照组（P＜0.05）。两组治疗后的心绞痛的发作频次、每次持续时间、数字疼痛强度量表（NRS-11）评分显著降低（P＜0.05）；治疗组治疗后的心绞痛的发作频次、每次持续时间、NRS-11评分均低于对照组（P＜0.05）。两组治疗后的左室射血分数（LVEF）、二尖瓣血流频谱的早期充盈速度与晚期充盈速度的比值（E/A）明显升高（P＜0.05），且治疗组治疗后LVEF、E/A明显高于对照组（P＜0.05）。两组治疗后的血清髓系细胞触发受体1（TREM-1）、内皮细胞特异性分子-1（ESM-1）、S100钙结合蛋白A4（S100A4）水平明显低于治疗前（P＜0.05）；治疗组治疗后的血清TREM-1、ESM-1、S100A4水平明显低于对照组（P＜0.05）。结论 复方血栓通胶囊联合盐酸阿罗洛尔片可提高不稳定型心绞痛的疗效，改善生活质量和减轻心绞痛症状，提高心功能，可能与减轻心肌炎性损伤有关。

Objective To investigate the clinical efficacy of Compound Xueshuantong Capsules combined with Arotinolol Hydrochloride Tablets in treatment of unstable angina pectoris. Methods 120 Patients with unstable angina pectoris who were treated at Xuzhou Central Hospital from March 2023 to January 2026 were divided into control group and treatment group using a random number table method, with 60 cases in each group. The control group was po administered with Arotinolol Hydrochloride Tablets at 1 tablet per time, twice daily. The treatment group received Compound Xueshuantong Capsules in addition to the control group's treatment, with 3 capsules per time, three times daily. Two groups were treated for 3 months. The clinical efficacy, Seattle Angina Questionnaire (SAQ) scores, angina symptom indicators, cardiac function indicators, and serum indicators were compared between two groups. Results The total effective rate of the treatment group was 93.33%, while the total effective rate of the control group was 78.33%, and the difference between two groups was significant (P < 0.05). After treatment, the SAQ scores of two groups increased (P< 0.05), and the SAQ score of the treatment group was significantly higher than that of the control group (P < 0.05). After treatment, the frequency, duration, and NRS-11 score of angina pectoris in two groups significantly decreased (P < 0.05). The frequency, duration, and NRS-11 score of angina pectoris in the treatment group were lower than those in the control group (P < 0.05). After treatment, the left ventricular ejection fraction (LVEF) and the ratio of early to late filling velocity (E/A) of mitral valve flow spectrum in two groups significantly increased (P< 0.05), and the LVEF and E/A in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the serum levels of myeloid cell trigger receptor 1 (TREM-1), endothelial cell specific molecule-1 (ESM-1), and S100 calcium binding protein A4 (S100A4) in two groups were significantly reduced (P < 0.05). The serum levels of TREM-1, ESM-1, and S100A4 in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion The combination of Compound Xueshuantong Capsules and Alolol Hydrochloride Tablets can improve the efficacy of unstable angina pectoris, improve quality of life, alleviate angina symptoms, and enhance cardiac function, which may be related to reducing myocarditis injury.

徐州市医学领军人才培养项目（XWRCHT20210032）